Brief: Vaxil Completes Oversubscribed Financing To Advance Cancer Immunotherapy Research
30/01/2018 13:30
Jan 30 (Reuters) - Vaxil Bio Ltd VXL.V :
* VAXIL COMPLETES OVERSUBSCRIBED FINANCING TO ADVANCE ITS
CANCER
IMMUNOTHERAPY RESEARCH AND DEVELOPMENT
Source text for Eikon: ID:nMKWMYs4ra
Further company coverage: VXL.V
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Vaxil Bio
See all newsBrief: Vaxil Announces Close Of Previously Announced Non-Brokered Private Placement
Brief: Vaxil Bio Says Proposed Reverse Takeover With Green Date Terminated
Brief: Vaxil Bio Enters Into Definitive Agreement With Green Data Centers for Reverse Take Over
Brief: Vaxil Bio To Continue Actively Explore Other Strategic Options
Brief: Vaxil Bio Enters Into Letter Of Intent With Copper Bullet Mines In Respect Of A Proposed Reverse Takeover